Oyster Point Pharma, Inc. Common Stock
OYST
OYST was delisted on the 30th of December, 2022.
60 hedge funds and large institutions have $331M invested in Oyster Point Pharma, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 28 increasing their positions, 12 reducing their positions, and 10 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 12
9% less funds holding
Funds holding: 66 → 60 (-6)
13% less capital invested
Capital invested by funds: $380M → $331M (-$48.5M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.61M |
| 2 |
First Manhattan
New York
|
+$1.51M |
| 3 |
Creative Planning
Overland Park,
Kansas
|
+$1.49M |
| 4 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$1.47M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$802K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$4.8M |
| 2 |
SCM
Sio Capital Management
New York
|
-$2.23M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.48M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$1.25M |
| 5 |
Millennium Management
New York
|
-$1.22M |
OYST Hedge Fund Activity: Q4 2020 in Review
60 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Oyster Point Pharma, Inc. Common Stock (OYST) for Q4 2020, worth a combined $331M — down 13% from $380M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of OYST and 5 opened new positions — a net loss of 5 holders — while 12 trimmed existing stakes and 28 added.
The largest buyer was Wellington Management Group, adding an estimated $1.61M. The largest seller was Emerald Mutual Fund Advisers Trust, cutting an estimated $4.8M.
- 60 institutional investors held Oyster Point Pharma, Inc. Common Stock (OYST) as of Q4 2020, down from 66 in Q3 2020.
- Funds reported $331M of Oyster Point Pharma, Inc. Common Stock stock for Q4 2020, down 13% quarter-over-quarter.
- 5 funds opened new Oyster Point Pharma, Inc. Common Stock positions in Q4 2020 and 10 closed out, a net change of -5 holders.
- The largest Oyster Point Pharma, Inc. Common Stock buyer in Q4 2020 was Wellington Management Group, an estimated $1.61M added.
- The largest Oyster Point Pharma, Inc. Common Stock seller in Q4 2020 was Emerald Mutual Fund Advisers Trust, an estimated $4.8M sold.
Based on aggregated 13F filings for Q4 2020.